6 Results for "

FVIIa

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "FVIIa" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-16382
CAS No.: 871266-63-6
Target:  

Factor VIIa

Research Areas:  

Cancer

PCI-27483 is a FVIIa/tissue factor inhibitor, with antitumour effects.
loading...
    loading...
Cat. No.: HY-114511
CAS No.: 1004551-40-9
Purity:  99.90%
Target:  

Factor VIIa

Research Areas:  

Cardiovascular Disease

BMS-593214 is an active site-directed factor (F) VIIa inhibitor. BMS-593214 shows antithrombotic and antihaemostatic properties. BMS-593214 is a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of Viia-activated substrate FX. BMS-593214 prevents electroinduced carotid artery thrombosis (AT) and wire induced vena cava thrombosis (VT) .
loading...
    loading...
Cat. No.: HY-P3235
CAS No.: 1926163-13-4
Target:  

Factor VIIa

Research Areas:  

Others

E-76 is a peptide with anticoagulant activity. E-76 inhibits blood coagulation by specifically binding to exogenous coagulation factor VIIa (FVIIa). E-76 can be used to study blood coagulation-related diseases .
loading...
    loading...
Cat. No.: HY-P991029
CAS No.: 2933972-64-4
Synonyms: HMB-001
Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia .
loading...
    loading...
Cat. No.: HY-172905
CAS No.: 885684-79-7
Target:  

Others

Research Areas:  

Cardiovascular Disease

BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor (IC50: 4 nM). BCX-3607 blocks the extrinsic coagulation pathway by inhibiting the TF-FVIIa complex and significantly prolongs the prothrombin time (PT). BCX-3607 has a higher selectivity for TF-FVIIa than other serine proteases (such as thrombin, FXa, etc.). BCX-3607 can reduce thrombus weight and inflammatory response, and has both anti-thrombotic and anti-inflammatory effects. BCX-3607 can be used in the study of thrombosis-related diseases .
loading...
    loading...
Cat. No.: HY-P992152
CAS No.: 897936-89-9
Synonyms: NN-1731

Research Areas:  

Cardiovascular Disease

Vatreptacog alfa is a recombinant hFVIIa analog, differing from native FVIIa by three amino acid substitutions (V158D, E296V and M298Q) in the protease domain. Vatreptacog alfa exhibits enhanced tissue factor-independent enzymatic activity toward activated platelets. Vatreptacog alfa can be used in the research of hemophilia .
loading...
    loading...